Skip to content

D&A at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$594M-41.3%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$351K-29.9%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$2.87M-7.4%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$91.58K+140%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$4.38M+14.4%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$79K+3.9%

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s D&A?
Artiva Biotherapeutics, Inc. (ARTV) reported D&A of $666K in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s D&A changed year-over-year?
Artiva Biotherapeutics, Inc.'s D&A increased by 6.1% year-over-year, from $628K to $666K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.